• Harold R Collard, Williamson Z Bradford, Vincent Cottin, Kevin R Flaherty, Talmadge E King, Gary G Koch, Martin Kolb, Fernando J Martinez, Bruce Montgomery, Ganesh Raghu, Luca Richeldi, Dan Rose, Athol U Wells, and Kevin K Brown.
• Dept of Medicine, University of California San Francisco, San Francisco, CA, USA hal.collard@ucsf.edu.
• Eur. Respir. J. 2015 Jul 1; 46 (1): 243-9.

AbstractThe past decade has seen substantial progress in understanding the pathobiology, natural history, and clinical significance of idiopathic pulmonary fibrosis (IPF), culminating in the establishment of two effective medical therapies. Now seems an important time to reconsider the design and conduct of future IPF clinical trials. Building on lessons learned over the past decade, we use this perspective to lay out four key considerations for moving forward effectively and efficiently with the next generation of clinical trials in IPF. These are: development of a coordinated IPF clinical trials network; establishment of expectations for early phase proof of concept studies; adaptation of late-phase efficacy trial designs to the emergence of approved therapies, and; agreement on primary end-points for late phase clinical trials. Continued progress in the field of IPF will require creativity and collaboration on the part of all stakeholders. We believe that addressing these four considerations will encourage and enable investment in this new era of drug development in IPF, and will lead to more rapid development of effective therapies. Copyright ©ERS 2015.

12 keywords...

hide…